Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)

Vertex Pharmaceuticals has reported Tax Provisions for 16 years, with the latest figure at $292.0 million in Q2 2026.

• On a quarterly basis, Tax Provisions rose 16.75% year-over-year to $292.0 million in Q2 2026; TTM through Jun 2026 was $869.3 million, a 18.05% increase from a year earlier, with the FY2025 full-year figure at $690.0 million, down 12.0% from the prior year.
• Tax Provisions was $292.0 million for Q2 2026 at Vertex Pharmaceuticals, up from $221.5 million in the prior quarter.
• The five-year high for Tax Provisions was $292.0 million in Q2 2026, with the low at $84.1 million in Q1 2025.
• Average Tax Provisions over 5 years is $203.2 million, with a median of $208.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions soared 292.36% in 2022, then plunged 53.15% in 2025.
• Over 5 years, Tax Provisions stood at $257.9 million in 2022, then slumped by 30.67% to $178.8 million in 2023, then increased by 25.0% to $223.5 million in 2024, then slumped by 37.4% to $139.9 million in 2025, then jumped by 108.72% to $292.0 million in 2026.
• The last three Tax Provisions figures came in at $292.0 million (Q2 2026), $221.5 million (Q1 2026), and $139.9 million (Q4 2025), per Business Quant data.